Different substrates of non-sustained ventricular tachycardia in post-infarction patients with and without left ventricular dilatation by Di Bella, Gianluca et al.
Journal of Cardiac Failure Vol. 16 No. 1 2010Different Substrates of Non-Sustained Ventricular Tachycardia
in Post-infarction Patients With and Without Left
Ventricular DilatationGIANLUCA DI BELLA, MD, PhD,1,2 CLAUDIO PASSINO, MD,1,3 GIOVANNI DONATO AQUARO, MD,1
DANIELE ROVAI, MD, FESC,1 ELISABETTA STRATA, MD,1 FRANCESCO ARRIGO, MD,2 MICHELE EMDIN, MD, PhD,1
MASSIMO LOMBARDI, MD,1 AND ALESSANDRO PINGITORE, MD, PhD1
Pisa, Italy; Messina, ItalyFrom the 1CNR




June 10, 2009; rev
Reprint reques
Physiology Institu






Background: We investigated the relationship between nonsustained ventricular tachycardia (NSVT) and
left ventricular (LV) dilatation, function, remodeling, and scar tissue extent in patients with previous
myocardial infarction (MI).
Methods and Results: Eighty-two patients (ages 646 10 years) with first previous MI were referred for
24-hour electrocardiogram recording and cine and delayed enhancement (DE) cardiac magnetic resonance
(CMR). LVvolumes, ejection fraction, systolicwall thickening, sphericity index, and core and peri-infarctual
areas of scar tissue by CMR were evaluated. LV dilatation was observed in 39 patients. Episodes of NSVT
were recorded in 32 patients: 23 with LV dilatation and 9without. In the entire population, NSVTwas related
to ejection fraction, LV volumes, LV mass, and sphericity index; end-systolic volume (P5 .001) resulted in
the only independent predictor at multivariate analysis. In patients without LV dilatation, the occurrence of
NSVTwas only positively related with percentage of contracting segments with DE (P5 .008). Conversely,
in patients with LV dilatation, increase in LV mass (P5 .020) and end-systolic volume (P5 .038) were in-
dependent predictors of NSVT.
Conclusions: Necrotic and viable myocardium coexistence within the same wall segments predicted
occurrence of NSVT in patients without LV dilatation, whereas LV mass and end-systolic volume were
predictors of NSVT in those with LV dilatation. (J Cardiac Fail 2010;16:61e68)
Key Words: Cardiac magnetic resonance, scar tissue, myocardial infarction.Although the use of an implantable cardioverter defibril-
lator (ICD) helps to prevent sudden cardiac death in pa-
tients at risk of fatal ventricular arrhythmias,1e6 objective
criteria for identifying those patients who would best bene-
fit from ICD implantation are still under investigation.
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61the only parameter used in deciding whether to perform
ICD implantation, a variety of markers derived from clini-
cal and instrumental data (12-lead electrocardiogram
[ECG], 24-h Holter ECG, electrophysiological studies, pa-
rameters of cardiac performance obtained with different
cardiac imaging techniques, and laboratory assays) has
been proposed as predictors of sudden cardiac death.7,8 Al-
though debated, nonsustained ventricular tachycardia (VT),
which is frequent in patients with dilated cardiomyopathy
ranging from 30% to 80%,9 has been identified as an inde-
pendent predictor of sudden death, as documented in
a meta-analysis of 11 peer-reviewed papers enrolling
more than 100 patients each.9e11 In addition, in the Multi-
center Unsustained Tachycardia Trial, the presence of non-
sustained VT and other variables increased the risk of
sudden death in patients with LV ejection fraction O30%,
resulting higher than that of patients with ejection fraction
!30% but without other risk factors.12 Other parameters
proposed as potential predictors of cardiac arrhythmic
62 Journal of Cardiac Failure Vol. 16 No. 1 January 2010risk include indices of LV remodeling, such as LV spheric-
ity index, LV mass/LV end-systolic volume, systolic and
diastolic LV volumes, parameters of global and regional
LV function, and extent of myocardial necrosis.7,8,13,14
The interactions between nonsustained VT and these vari-
ables are not well-defined in patients with postischemic
LV dysfunction with and without LV enlargement.
Cardiac magnetic resonance (CMR) accurately quantifies
LV volumes and function, and provides unique information
on LV remodeling and indices of regional and systolic func-
tion, as well as the extent of both myocardial necrosis and
peri-infarctual tissue (‘‘gray zone’’).15e17
Thus the aim of this study was to investigate the interac-
tions between occurrence of episodes of nonsustained VT
and CMR parameters of LV remodeling, function and myo-




A total of 283 consecutive inpatients with previous MI (longer
than 3 months) underwent routine CMR clinical scan to assess
scar tissue extent and LV function and volumes. During hospitaliza-
tion, all patients underwent stress echocardiography or stress
scintigraphy. Of these, 201 patients were excluded according to
the following exclusion criteria: multiple MIs (n5 90) to avoid
the confounding role ofmultiple scarring in predicting nonsustained
VT; documentedmyocardial ischemia at stress echocardiography or
stress scintigraphy (n5 85); amiodarone therapy (n5 22); other
concomitant cardiomyopathies (n5 3); and previous cardiac
resuscitation, except in the acute phase of the MI (n5 1).
The final population consisted of 82 inpatients (ages 646 10
years, 9 female) with a single previous MI without inducible
ischemia at stress test. All patients underwent 24-hour Holter
ECG immediately before the CMR exam. The study was approved
by the local ethics review committee, and the investigation
conformed to the principles outlined in the Declaration of Helsinki.
All patients gave their informed consent before the study.
CMR Data Acquisition
The protocol consisted in evaluating by cine CMR the LV vol-
umes, global LV function, quantitative wall motion by measuring
systolic wall thickening (SWT), and by delayed enhancement
(DE), the core, gray zone, and transmural extent of myocardial
necrosis. CMR was performed using a 1.5 T whole-body scanner
(GE Medical Systems, Milwaukee, WI). A 4-element cardiac
phased-array receiver surface coil was used for signal reception.
A breath-hold segmented-gradient echo fast imaging employing
steady-state acquisition (FIESTA) ECG-triggered sequence was
used to evaluate global LV function according to standard param-
eters. In each patient, a total of 9 to 12 short-axis views (depend-
ing on the LV volume, with a slice thickness of 8 mm and no
interslice gap) and 2 long-axis views (1 vertical and 1 horizontal)
were acquired, with a minimum of 30 cine frames for each slice.
DE images were obtained 8 to 10 minutes after bolus injection of
gadobutrol (Gadovist, Schering, Germany; 0.2 mmol/kg); images
were acquired in the same short-axis and long-axis slices as
used for cine CMR. A fast gradient echo inversion recoverysequence was used with the following parameters: repetition
time 4.2 ms, echo time minimum, flip angle 20, matrix
256 192, number of excitations 1.00, field of view 36 to
42 mm, slice thickness 8 mm, and no inter-slice gap. The inversion
time was optimized to null signal from the normal myocardium.CMR Data Analysis
To determine LV function, endocardial borders were manually
drawn on all LV short-axis images by means of previously vali-
dated software (Mass, MEDIS, The Netherlands).
LV end-systolic volume (LV-ESV) and end-diastolic volumes
(LV-EDV) were then calculated and LVEF was derived. According
to normal ranges for steady-state free precession sequences,18
a cutoff of LV-EDV of 112 mL/m2 was used to identify 2 groups
of patients: a group with LV dilatation and a group with no LV
dilatation. Diastolic sphericity index was obtained as follows:
LV-EDV ([longest LA/2]3 * 4,187) using the longest long axis
(LA) obtained from the 2- or 4-chamber views.19 The ratio
EDV/mass and sphericity index at diastole were considered as
LV remodeling indexes.19,20 Three short-axis images correspond-
ing to basal, middle, and distal levels of the LV were used to quan-
tify wall thickness at end-diastole and end-systole for the
calculation of SWT in 16 segments of LV (the apex was excluded).
A value of SWT greater than 10% for each segment was consid-
ered as contracting myocardium.21
As previously described,17 to quantify tissue heterogeneity of
DE areas, myocardial segments containing the region of high sig-
nal intensity (SI) myocardium were outlined, and the maximum SI
within this region was determined. The infarct core extent was
then defined as myocardium with SI O50% of the maximal SI.
A region of interest (ROI) was then placed by a trained observer
in an area free of artifacts and with uniform myocardial suppres-
sion of the remote myocardium. The gray zone of infarct periphery
was defined as the myocardium with SIO peak remote but!50%
of maximal SI of the high SI myocardium (Fig. 1). For each pa-
tient, the infarct core and gray zone in each short-axis slice
were planimetered, and the global size was expressed as percent-
age of the entire LV myocardium.
The transmural extent of hyperenhancement was measured by
standard techniques.17 For each segment, the transmural extent
of total hyperenhancement was expressed as percentage of total
segment area. For each patient, the percentage of segments with
transmural extents of hyperenhancement within each quartile
(0%e25%; 26%e50%; 51%e75%; or O75%) was determined.
Furthermore, the relation between SWT and DE allowed us to
classify each segment as follows: contracting segments (SWT
O10%) with DE, contracting segments (SWT O10%) without
DE, noncontracting segments (SWT !10%) with DE, and
noncontracting segments (SWT !10%) without DE (Fig. 2).
These segments represent the combined information about
tissue characterization and segmental systolic function of LV myo-
cardium (Fig. 2). Contracting segments with DE (CT-DE) identify
a tissue with previous necrosis and preserved contraction; the cor-
onary flow related to these segments is almost certainly preserved.
No contracting segments with DE (noCT-DE) identified a tissue
with previous necrosis and without contraction: the likelihood of
improvement in regional contractility after possible revasculariza-
tion decreased progressively with the transmural extent of DE.22
No contracting segments without DE (noCT-noDE) represent
a tissuewithout necrosis butwith depressed segmental systolic func-
tion, probably from reduced coronary flow reserve: this tissue can be
Fig. 1. Gray zone and core measurement. Delayed enhancement short-axis magnetic resonance images from left ventricular (LV) base to LV
apex of a patient with an anterior infarct. Computer-assisted, semiautomatic technique for quantifying infarct core and gray zone on de-
layed-enhancement images. Black area corresponds to infarct core, gray area to peri-scar tissue and white area to normal myocardium.
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without DE (CT-noDE) identify a normal myocardium. All data ob-
tained by CMR exam were blinded to the Holter ECG results.Holter Monitoring
A 24-hour Holter ECG recording was performed in all patients
the day before the CMR examination using a commercial system
(Elamedical, Synescope, Cedex, France).
The parameters analyzed were the number of premature ventric-
ular complexes (PVCs) and the presence of episodes of ventricularFig. 2. Illustration of pattern of segments in the relation between
systolic wall thickening (SWT) and delayed enhancement (DE).tachycardia (VT) defined as O3 consecutive ventricular contrac-
tions with a ventricular rate O100 beats/min.
Statistical Analysis
Continuous variables are expressed as mean6 SD and categor-
ical variables as percentages. Continuous variables with a skewed
distribution were logarithmically transformed for further statistical
analysis. Unpaired t-test was used to assess the differences be-
tween the groups with and without LV dilatation or with and with-
out nonsustained VT. The strength of correlation between
variables was assessed by Pearson coefficient (R). Continuous var-
iables (age, EDV, ESV, EF, mass/EDV, sphericity index, SWT, in-
farct core and gray zone, total DE [core þ gray zone], contracting
segments without DE (CT-noDE), non-contracting segments with-
out DE (noCT-noDE), non-contracting segments with DE (noCT-
DE), contracting segments with DE (CT-DE), DE transmural
extent 1%-25%, 26%e50%, 51%e75%, 76%e100%), and cate-
gorical variables (gender, hypertension, obesity, diabetes, dyslipi-
demia, smoking, medical treatment, New York Heart Association
Class), were entered into a univariate, logistic regression model to
identify predictors of nonsustained VT in the entire population and
in the subsets with and without LV dilation. Univariate predictors
were then entered in a multivariate logistic regression model. A P
value less than .05 was considered to be statistically significant.
All analyses were performed using SPSS for Windows (version
11.00; SPSS Inc, Chicago, IL).
Results
Of the entire population of 82 patients, 43 (52%) had LV
dilatation, whereas 39 patients (48%) had preserved LV
Table 1. Baseline Characteristics of the Entire Population and of Patients with and without LV Dilatation
Entire Population (n5 82) No LV Dilatation (n5 39) LV Dilatation (n5 43) P Value
Age (y) 646 10 666 8 626 12 NS
Male (%) 89 82 95 NS
Family history of CAD (%) 48 49 48 NS
Hypertension (%) 58 60 56 NS
Diabetes (%) 30 31 42 NS
Hypercholesterolemia (%) 50 46 56 NS
Smoker (%) 45 44 45 NS
BMI O30 (%) 19 22 17 NS
Q-wave MI (%) 71 80 61 NS
Anterior MI (%) 62 63 60 NS
NYHA OII (%) 16 0 34 !0.0001
Number of stenosed vessels 1.96 0.8 1.86 0.6 2.16 0.8 NS
Syncope (%) 6 3 10 NS
ICD implantation (%) 23 10 33 0.008
b-blocker (%) 76 76 76 NS
ACE-I/ARB (%) 83 81 84 NS
Spironolactone (%) 29 16 42 0.02
Digoxin (%) 13 3 24 0.01
CMR-MI interval (months) 786 77 686 81 856 73 NS
BMI, body mass index; MI, myocardial infarction; NYHA, New York Heart Association; CAD, coronary artery disease; ICD, implantable cardioverter
defibrillator, ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CMR, cardiac magnetic resonance.
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the 2 subsets with and without LV dilatation are shown in
Table 1. During hospitalization, 19 (23%) patients (5 with-
out and 14 with LV dilatation) received an implantable car-
dioverter device after the execution of CMR examination,
according to Second Multicenter Automated Defibrillator
Implantation Trial criteria.CMR Variables and Arrhythmic Profile at Holter
Monitoring
Ahigh percentage (85%) of contracting segments with DE
had a transmural extent#50%,whereas 72% of noncontract-
ing segments with DE had aO75% transmural extent of DE.
During Holter monitoring the number of PVCs (expressed by
log10 of PVCs) was significantly more frequent in patients
with LV dilatation than in those without LV dilatation
(2.916 0.83 vs. 1.826 1.1 P ! .001). Considering the
whole population, a positive correlation was found between
the number of PVCs and EDV (R5 0.63, P ! .001), ESV
(R5 0.66, P ! .001,), and sphericity index (R5 0.50,
P ! .001). A correlation was also found with total extent
ofDE (coreþgray) (R5 0.39,P5 .01), noncontracting seg-
ments with DE (R5 0.44, P5 .001). Conversely, a negative
correlation was observed among number of PVCs and EF
(R50.58, P ! .001), SWT (R 5 0.54, P ! .001),
mass/EDV (R50.55,P! .001), and contracting segments
without DE (R5 0.27, P5 .02). In patients with LV dila-
tation, the number of PVCs was related to EDV (R5 0.51,
P5 .001), ESV (R5 0.60, P # .001), EF (R50.40,
P5 .01), mass/EDV (R50.38, P5 .02), and sphericity
index (R5 0.49, P5 .004). In patients without LV dilata-
tion, EDV (R5 0.33, P5 .04), and ESV (R5 0.40,
P5 .01) correlated with the number of PVCs.
Holter-ECG monitoring showed no episodes of sustained
VT in any patient. Episodes of nonsustained VT occurred in32 patients: 23 with and 9 without LV dilatation. The inci-
dence of nonsustained VT was significantly different in the
2 subsets. The CMR variables of the patients with and with-
out nonsustained VT are shown in Table 2.CMR Variables in Dilated and Nondilated LV
Compared with patients with no LV dilatation, those with
LV dilatation had a significantly lower EF and mass/EDV
ratio and SWT, higher LV mass, sphericity index, and
a greater gray zone and total extent of DE than those
with normal LV volumes (Table 3). Moreover, patients
with LV dilatation had lower percentage of contracting seg-
ments without DE and higher percentage of noncontracting
segments with DE (Table 3).Predictors of Nonsustained VT
In the entire population at univariate analysis, EDV, ESV,
EF, LV Mass, LV mass/EDV, and sphericity index were pre-
dictors of occurrence of nonsustained VT (Table 4). Multi-
variate analysis selected ESV as the only independent
predictor of nonsustained VT (Table 4).
In the subset of patients with LV dilatation, variables able
to predict occurrence of nonsustained VT were: EDV
(HR 1.024, CI 1.003e1.046, P5 .023), ESV (HR 1.024,
C.I. 1.004e1.044, P5 .016), and LV mass (HR 1.047,
C.I. 1.007e1.088, P5 .012). Multivariate analysis selected
LV mass (HR 1.047, C.I. 1.007e1.088, P5 .020) and ESV
(HR 1.027, C.I. 1.002e1.053, P5 .038) as independent
predictors of nonsustained VT. Conversely, in patients
with preserved LV volumes, the percentage of contracting
segments with DE (HR 1.116, C.I. 1.029e1.210,
P5 .008) was the only predictor of nonsustained VT at
univariate analysis.




Presence (n5 32) P Value
LV-EDV (mL/m2) 1166 39 1636 54 !.0001
LV-ESV(mL/m2) 786 40 1296 45 !.0001
LV-EF (%) 366 13 266 12 .001
LV mass (gr/m2) 826 21 976 27 .02
LV mass/EDV (gr/ml) 0.786 0.3 0,626 0,2 .02
Sphericity index 0.546 0.1 0,666 0,2 .003
SWT 306 19 236 17 NS
Extent of DE
Infarct core 166 8 156 10 NS
Gray zone (%) 146 8 146 10 NS
Total (core þ gray) (%) 286 13 306 16 NS
Transmural infarct extent: % of segments grouped by
quartiles of transmurality
No infarct 486 20 486 18 NS
1% to 25% infarct transmurality 6.46 13 7.76 9 NS
26% to 50% infarct transmurality 5.26 6 66 6 NS
51% to 75% infarct transmurality 196 13 206 13 NS
76% to 100% infarct transmurality 216 18 1886 18 NS
CT-noDE (%) 396 24 336 20 NS
noCT-noDE (%) 106 13 176 17 NS
noCT-DE (%) 276 17 296 17 NS
CT-DE (%) 196 17 216 16 NS
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; SWT, systolic wall thickening; DE, delayed contrast en-
hancement; CT-noDE, contracting segments without DE; noCT-noDE, no-contracting segments without DE; noCT-DE, noncontracting segments with DE;
CT-DE, contracting segments with DE; VT, ventricular tachycardia.
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This study shows that the occurrence of nonsustained VT
is influenced by different factors in post-MI patients
according to the presence or absence of LV dilatation. In
particular, an index of LV remodeling as the ESV is the
only independent predictor of nonsustained VT in the entire
population; ESV and LV mass are predictor of NSVT in
patients with LV dilatation, whereas an index of mixed
myocardial necrosis/viabilitydderived from the combined
analysis of DE with SWTdis a predictor of nonsustained
VT in post-MI patients without LV dilatation. These results
suggest that the substrate for LV arrhythmias may differ in
post-MI patients: on 1 hand, LV geometry, more than mere
contractility (as expressed by the EF), is the main determi-
nant of ventricular arrhythmias in patients with LV dilata-
tion; on the other hand, the coexistence of necrotic and
viable contracting tissue within the same segment proves
to be the major trigger of ventricular irritability in nondi-
lated LV patients.
Postischemic LV Remodeling and Arrhythmogenic Risk
Our findings are consistent with the evidence that postis-
chemic LV dilatation and remodeling are critical risk deter-
minants of ventricular arrhythmias.8,23 Sutton et al showed
a relation between LV dimensions and LV mass with ven-
tricular arrhythmias, both early and late (up to 2 years) after
MI.8 Moreover, LV dilatation, but not dysfunction, was
found to be related to signs of electrical instability, suggest-
ing that LV remodeling might act as a common determinant
of electrical instability and sudden death.24 Furthermore,cardiac remodeling proved to be linked with other factors
predisposing to arrhythmias, including increased sympa-
thetic activity and myocardial adaptive phenomena, such
as hypertrophy, apoptosis, myosin isoform change, and
alterations in the cellular matrix.25,26
Myocardial Necrosis and Arrhythmogenic Risk
Previous studies have shown that scar tissue is an impor-
tant predictor of ventricular arrhythmias in both ischemic
and nonischemic cardiomyopathies.27e33 The relation
between occurrence of nonsustained VT and the percentage
of contracting segments with DEdan index of coexistence
of necrosis and viability within the same myocardial seg-
mentdsuggests that this particular tissue may be a substrate
for arrhythmogenesis, due to the coexistence of low-voltage
dense fibrosis areas, eliciting conduction block, and viable
myocardium, producing slow-conduction path circuits and
thus promoting intramural re-entry.34e36
More recently, the extent of peri-infarct or gray zone at
DE-CMR has acquired an important pathophysiological sig-
nificance. The gray zone is strongly associated with ventric-
ular irritability by programmed electrical stimulation during
electrophysiological study.17 In addition, the gray zone may
have a prognostic role in predicting cardiovascular mortality
in patients with previousMI.16 In our study, gray zone and to-
tal extent of DE were significantly higher in patients with di-
lated LV volumes. The gray zone did not correlate to PVCs,
nor to nonsustained VT. This discrepancy could be attributed
to the different ‘‘end points’’ considered (ie, spontaneous
nonsustained VT vs. induced monomorphic ventricular
tachycardia during electrophysiological study), but also to






(n5 43) P Value*
LV-EDV (mL/m2) 1346 50 926 17 1736 38 !.001
LV-ESV(mL/m2) 976 52 546 16 1366 42 !.001
LVEF (%) 326 14 416 11 236 10 !.001
LV mass (gr/m2) 846 24 786 22 986 22 !.001
LV mass/EDV 0.76 0.3 0.96 0.3 0.66 0.1 !.001
Sphericity index 0.596 0.16 0.496 0.14 0.676 0.14 !.001
SWT 286 19 386 17 166 13 !0.0001
Extent of DE
Infarct core (%) 156 9 146 7 176 9 NS
Gray zone (%) 146 9 126 7 166 11 .03
Total (core þ gray) (%) 296 14 256 111 346 17 .01
Transmural infarct extent: % of segments grouped by
quartiles of transmurality
No infarct 486 19 506 22 466 16 NS
1% to 25% infarct transmurality 6.96 12 6.46 13 7.86 10 NS
26% to 50% infarct transmurality 5.46 6 5.26 6 66 6 NS
51% to 75% infarct transmurality 19.56 13 19.36 12.7 19.96 13 NS
76% to 100% infarct transmurality 20.66 18 21.86 17 25.86 21 NS
CT-noDE (%) 376 23 466 23 306 20 .002
noCT-noDE (%) 136 15 96 11 166 17 NS
noCT-DE (%) 286 17 196 12 356 17 !.001
CT-DE (%) 206 16 216 16 196 17 NS
Nonsustained VT (%) 39 23 53 .004
LV, left ventricular; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; SWT, systolic wall thickening; DE, delayed contrast en-
hancement; CT-noDE, contracting segments without DE; noCT-noDE, no-contracting segments without DE; noCT-DE, no-contracting segments with DE;
CT-DE, contracting segments with DE; VT, ventricular tachycardia.
*Referring to comparison between the two subsets of patients with or without LV dilatation.
66 Journal of Cardiac Failure Vol. 16 No. 1 January 2010differences in patient characteristics (all patients enrolled in
the study by Schmidt et al had clinical indications of ICD vs
only 36% of our population).17
Clinical Implications
Patients with postischemic LV dysfunction and nonsus-
tained VT represent a worrisome group at higher risk of
sudden death.37e39 The observation that a combination of
subendocardial necrosis and preserved contractility is
a predictor of arrhythmic risk only in patients without LV
enlargementdbut not in dilated LV patients with LV dys-
functiondsuggests that the weight of each variable in pre-
dicting arrhythmic risk may be related to morphological
and functional LV status. Moreover, in the subset of
patients with LV dilatation and dysfunction, indexes of geo-
metrical remodeling (namely the ESV) seem to be more
effective in identifying patients at higher arrhythmogenic
risk when compared to indexes of contractility commonlyTable 4. Predictor of Nonsustained Ventricular Ta
Univariate Analysis
HR (95% CI) P V
EDV(mL/m2) 1.021 (1.010e1.033) .0
ESV(mL/m2) 1.022 (1.011e1.033) .0
EF (%) 0.937 (0.901e0.975) .0
LV Mass (gr/m2) 1.026 (1.004e1.048) .0
LV mass/EDV 0.083 (0.009e0.784) .0
Sphericity index 1.053 (1.014e1.093) .0
EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction.employed in clinical guidelines (ie, EF). This hypothesis
implies that any arrhythmic risk stratification algorithm
may be effective in selected patients with LV dysfunction
having similar characteristics of LV morphology and func-
tion. Therefore, in a large heterogeneous group of patients
with postischemic LV dysfunction and nonsustained VT
a multimarker strategy might be necessary to better stratify
patients at high arrhythmic risk.
Limitations of the Study
The small number of patients and events (nonsustained
VT) are this study’s main limitations. However, LV func-
tion and morphology were assessed by CMR, a noninvasive
and nonionizing technique considered the gold standard
approach to assessing volumes and regional and global
function of LV. The high quality of imaging and the 3-
dimensional approach of CMR allows assessment of LV
postischemic remodeling accurately and with highchycardia in the Entire Population (n5 82)
Multivariate Analysis
alue HR (95% CI) P Value
01 d
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reproducibility, enabling the smaller sample size to reach
statistical significance.40,41
It is uncertain whether nonsustained VT can be consid-
ered a true or surrogate marker of sudden death in patients
with postischemic LV dysfunction because there is no clear
evidence of its prognostic potential.39e44 Although it
assumes increasing importance when combined with evi-
dence of myocardial dysfunction, becoming a better prog-
nostic predictor of cardiac death than electrophysiological
testing,45 the status of nonsustained VT is often not known,
and determining its presence or absence is not straightfor-
ward, because its detection depends on the frequency of
nonsustained VT episodes and the duration of monitoring.
Moreover, detection during prolonged in-hospital monitor-
ing is more likely but may be associated with a different
prognosis.46
Conclusion
The results of this study show that morphological and
functional variables have different weight in predicting non-
sustained VT in patients with previous MI; LV remodeling
indices are important in the general population and in patients
with dilated LV, whereas regional systolic function with
mixed necrotic and viable tissue in patients without LV dila-
tation. In this context, CMR may be an appropriate noninva-
sive and nonionizing imaging technique for accurately
assessing, in a ‘‘one-shop stop’’ modality, morphology, func-
tion and necrosis extent in post-MI patients. Further studies
are needed to define this hypothesis.
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